A distinct CAR-T cell phenotype mediates therapeutic response at limited doses.
A specific type of CAR-T immune cell signature predicts treatment success regardless of dose, potentially enabling effective therapy with fewer manufactured cells.
Using deep phenotyping of anti-CD19 CAR-T products from the Phase I/II HD-CAR-1 basket trial, this study identified a distinct functional effector/memory-like CAR-T phenotype that predicts clinical response independent of dose and CAR-T target, with leukapheresis myeloid cell composition as a key upstream determinant. The findings provide a validated cross-target biomarker for response at limited doses and define new strategies for overcoming manufacturing-dose constraints.
What the study was
- Study design
- Phase I/II dose-escalation basket trial with deep single-cell phenotyping (HD-CAR-1, NCT03676504)
- Population
- Relapsed/refractory B-cell lymphoma (DLBCL, FL, MCL) receiving anti-CD19 CAR-T
- Category
- Treatment Innovation
- Maturity
- Potentially Practice-Changing
- Journal
- Nature Communications
Why it surfaced
Phase I/II CAR-T basket trial identifying a robust phenotypic biomarker of response at limited doses—addresses a critical manufacturing and clinical gap; Nature Communications, open access.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.